Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.13 +1.51 (+1.49%)
Streaming Delayed Price Updated: 1:16 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
96 97 Next >
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
Merck, Ridgeback Withdraw COVID-19 Pill European Application Amid Regulatory Hurdles
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have reportedly withdrawn their COVID-19 pill application in the European Union (EU). 
Via Benzinga
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
Developmental biomedical device company PetVivo Holdings Inc. (NASDAQ: PETV) makes pet medical devices and therapeutics. What kind of medical devices would 
Via MarketBeat
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Merck & Co Unusual Options Activity For June 21
Via Benzinga
Is Merck Stock a Top Buy Right Now?
The drugmaker is still a work in progress. 
Via The Motley Fool
2 Healthcare Stocks That Could Make You Richer
Both companies are proven innovators. 
Via The Motley Fool
Merck & Co Accused of Underplaying Mental Health Risks from Asthma and Allergy Drug Singulair
Initially, when released in 1998, Merck & Co Inc's (NYSE: MRK) asthma and allergy drug, Singulair, claimed side effects were mild and similar to a placebo, and the label stated that its distribution in... 
Via Benzinga
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
Wall Street Says This Beaten-Down Stock May Climb Nearly 78%. Is That Too Optimistic?
Can former high-flyer Moderna soar again? 
Via The Motley Fool
MRK: Garner Income From This Pharma Giant
Merck & Co. has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems right for a mature industry. 
Via Talk Markets
Dear SCHD ETF Fans, Mark Your Calendars for June 26
Fans of the Schwab US Dividend Equity ETF (SCHD) will want to keep an eye on the company when June 26 rolls around for a dividend payment. 
Via InvestorPlace
Pharmaceutical Lobbying Group Challenges Biden Administration Over Medicare Price Negotiations
The Pharmaceutical Research and Manufacturers of America (PhRMA), the National Infusion Center Association, and the Global Colon Cancer Association have filed a lawsuit against the Biden administration... 
Via Benzinga
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
Merck Says Keytruda Regimen Fails To Improve Event-Free Survival In Gastric Cancer Patients
Merck & Co Inc (NYSE: MRK) announced topline results from the Phase 3 KEYNOTE-585 trial of Keytruda (pembrolizumab) in combination with chemotherapy as a  
Via Benzinga
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Got $5,000? Buy These 2 Stocks and Hold Them Until Retirement
Not every familiar name is a company you can comfortably tuck away in your portfolio for decades, but these two are. 
Via The Motley Fool
Merck Completes Acquisition of Prometheus Biosciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare Form Of Gastric Cancer
Merck & Co Inc (NYSE: MRK) announced topline data from the Phase 3 KEYNOTE-811 trial of Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for human epidermal growth factor receptor 2... 
Via Benzinga
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
ChatGPT Portfolio Is Beating Most Funds: Is AI The Future Of Investing?
Via Benzinga
Why Are IO Biotech Shares Trading Lower Today
IO Biotech (NASDAQ: IOBT) randomized 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in  
Via Benzinga
Eli Lilly CEO Joins Other Pharma Execs, Raises Concern Over Medicare Price Negotiations Impacting Drug Development
Eli Lilly And Co (NYSE: LLY) CEO David Ricks voiced his concerns about the potential impact of Medicare price negotiations on drug development, which aim to reduce costs for older Americans.  
Via Benzinga
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)
From Merck & Co., Inc.
Via Business Wire
Merck Enters The Ring In Weight Loss — But Novo, Lilly Could Be The Winners
This update in nonalcoholic steatohepatitis helps prove the benefit of GLP-1 in the liver disease. 
Via Investor's Business Daily
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies. 
Via Benzinga
Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
From Merck & Co., Inc.
Via Business Wire
This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street
A big turnaround could be in the cards for this medical device maker. 
Via The Motley Fool
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.